Active Ingredient(s):Insulin Glargine + Lixisenatide FDA Approved: * November 21, 2016 Pharm Company: *SANOFI AVENTIS US Category:Diabetes
Lixisenatide (trade name Lyxumia in the European Union and Adlyxin in the U.S. and manufactured by Sanofi) is a once-daily injectable GLP-1 receptor agonist for the treatment of type 2 diabetes.
1 Medical use
1.1 Lixisenatide in neurodegenerative diseases
2 Adverse effects
3 Mechanism of action
7 External links
Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes. In the European Unio...
* May have multiple approval dates, manufacturers, or labelers.